Health-Related Quality-of-Life in post-menopausal women with Osteoporosis and Metabolic Syndrome
Dr. Santiago Palacios
Disclosure : This study was funded by Pfizer Inc. All authors had complete access to the data, participated in the analysis and/or interpretation of results, and drafted the abstract. Susana Fernández de Cabo, José Chaves and Javier Rejas are employees of Pfizer, S.L.U. All other authors declare no conflicts of interest.
9 slide(s) – English – 2012-03-28
Objective. To investigate the impact of co-morbid metabolic syndrome (MS) on Health-Related Quality-of-Life (HRQoL) in post-menopausal women with osteoporosis.
Methods. A cross-sectional, epidemiological study was designed including post-menopausal women (at least 12-month after last menstrual period) with osteoporosis, above 18-years old, who were attending outpatients clinics of Gynecology. HRQoL was recorded using the menopause specific Cervantes scale (higher score equivalent to worse HRQoL) and the generic SF-12v2 questionnaire. MS was defined according to the modified NCEP-ATP III criteria.
Results. 2,003 women with osteoporosis (bone densitometry <-2.5 t-score) and a mean (SD) age of 61.5 (7.6) years were analyzed. MS was observed in 415 (20.7%) of subjects. After adjusting by age and previous bone fracture, osteoporosis with MS was related with worse HRQoL in both the Cervantes and in the SF-12v2 scales; mean Z-score (95% CI) in Cervantes total score was +0.44 (0.35;0.53) in women with MS vs. +0.08 (0.03;0.12) in subjects without MS, p<0.001. Summary and all domains of the SF-12v2 were significantly lower in women with osteoporosis and MS in comparison with those without MS; -0.99 (-1.08; -0.90) and -0.55 (-0.64;-0.45) in summary physical and mental domains, respectively, vs. -0.60 (-0.64;-0.55) and -0.19 (-0.23;-0.14) in women without MS, p<0.001 in all cases. Clinical relevance of differences were moderate (effect sizes > 0.50) in most domains.
Conclusions. This study documented a loss of quality of life, relative to both reference post-menopausal patients and women of the general reference population, in post-menopausal women with concomitant osteoporosis and metabolic syndrome.